References
- Schneider G, Nienhaus K, Gromoll J, et al. Aging males' symptoms in relation to the genetically determined androgen receptor CAG polymorphism, sex hormone levels and sample membership. Psychoneuroendocrinology 2010;35:578–87
- Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab 2006;91:4335–43
- Mulligan T, Frick MF, Zuraw QC, et al. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract 2006;60:762–9
- Hill JO, Peters JC. Environmental contributions to the obesity epidemic. Science 1998;280:1371–84
- Nestle M, Jacobson MF. Halting the obesity epidemic: a public health policy approach. Public Health Rep 2000;115:12–24
- Wild S, Roglic G, Green A, et al. Global prevalence of diabetes. Estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047–53
- Huang HF, Nieschlag E. Suppression of the intratesticular testosterone is associated with quantitative changes in spermatogonial populations in intact adult rats. Endocrinology 1986;118:619–27
- Sharpe RM, Donachie K, Cooper I. Re-evaluation of the intratesticular level of testosterone required for quantitative maintenance of spermatogenesis in the rat. J Endocrinol 1988;117:19–26
- Qoubaitary A, Meriggiola C, Ng CM, et al. Pharmacokinetics of testosterone undecanoate injected alone or in combination with norethisterone enanthate in healthy men. J Androl 2006;27:853–67
- You-Lun G, Chang-Hai H, John KA, et al. Male hormonal contraception: suppression of spermatogenesis by injectable testosterone undecanoate alone or with levonorgestrel implants in Chinese men. J Androl 2004;25:720–7
- WHO. WHO laboratory manual for the examination and processing of human semen – 4th ed. Geneva: WHO
- Swerdloff RS, Wang C, Cunningham G, et al. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab 2000;85:4500–10
- Wang C, Berman N, Longstreth JA, et al. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study. J Clin Endocrinol Metab 2000;85:964–9
- Swerdloff RS, Wang C, Cunningham G, et al. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab 2000;85:4500–10